abstract_id,session_title,abstract_title,ground_truth,default_model_primary_drugs,default_model_secondary_drugs,default_model_comparator_drugs,default_model_reasoning,default_model_success,default_model_llm_calls
6022,,"A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma",,"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone"", ""Orelabrutinib"", ""Chidamide"", ""Venetoclax"", ""Lenalidomide"", ""Penpulimab""]",[],"[""RCHOP-X"", ""Pola-Rchp""]","[""1. Identified the core comparison structure using the keyword 'Versus'."", ""2. Extracted the drugs from the primary study arm: 'Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab'."", ""3. Classified all these individual drugs as Primary based on the 'Combined with' identifier."", ""4. Excluded the regimen abbreviation 'Pola-RCHP-X' because its full components were listed, following the exclusion rule."", ""5. Identified the comparator arms following 'Versus' as 'RCHOP-X' and 'Pola-Rchp'."", ""6. Classified 'RCHOP-X' and 'Pola-Rchp' as Comparator drugs, retaining the abbreviations as their components were not expanded in this context."", ""7. Confirmed no keywords indicating Secondary drugs were present."", ""8. Formatted the final lists and constructed the JSON output.""]",True,1
148,,Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial,,"[""BrECADD"", ""eBEACOPP""]",[],[],"[""1. Scanned the title for potential drug or regimen names."", ""2. Identified two abbreviated regimens: 'BrECADD' and 'eBEACOPP'."", ""3. The keyword 'and' connecting 'BrECADD' and 'eBEACOPP' indicates they are both primary treatments being studied."", ""4. Classified 'BrECADD' and 'eBEACOPP' as Primary Drugs."", ""5. Excluded 'Chemotherapy' as it is a broad therapy term."", ""6. Confirmed no secondary or comparator drugs were mentioned."", ""7. Formatted the output into the final JSON structure.""]",True,1
671,,Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma:a Phase 2 Multicenter Study,,"[""R-MINE""]",[],[],"[""1. Scanned the title for drug names, regimens, and classification keywords."", ""2. Identified 'R-MINE' as a drug regimen."", ""3. Identified 'Novel Targeted Agents' as a general class, not a specific drug, and therefore excluded it per the rules."", ""4. The phrase 'in Combination with' indicates that R-MINE is a core part of the treatment being studied."", ""5. Classified 'R-MINE' as a Primary drug regimen."", ""6. Found no keywords indicating Secondary or Comparator drugs."", ""7. Constructed the final JSON object with the extracted drugs and reasoning.""]",True,1
4792,,"A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics",,"[""Glofitamab"", ""R-CHOP"", ""Polatuzumab Vedotin"", ""R-CHP""]",[],[],"[""1. Identified potential drug and regimen candidates from the title: 'Glofitamab-R-CHOP', 'Glofitamab-Polatuzumab Vedotin-R-CHP', and 'FDG-PET'."", ""2. Analyzed the keyword 'or' which separates the two main treatment arms, indicating both are primary study arms."", ""3. Decomposed the regimens into their individual components: Glofitamab, R-CHOP, Polatuzumab Vedotin, and R-CHP."", ""4. Classified all identified therapeutic components (Glofitamab, R-CHOP, Polatuzumab Vedotin, R-CHP) as Primary based on the 'or' keyword."", ""5. Excluded 'FDG-PET' as it is a diagnostic procedure for response assessment, not a therapeutic agent administered for treatment."", ""6. Formatted the final list of drugs and constructed the JSON output with empty arrays for Secondary and Comparator drugs.""]",True,1
2723,,Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel,,"[""Idecabtagene Vicleucel"", ""Ciltacabtagene Autoleucel""]",[],[],"[""1. Scanned the title for potential drug names and classification keywords."", ""2. Identified 'Idecabtagene Vicleucel' and 'Ciltacabtagene Autoleucel' as candidate drugs."", ""3. The keyword 'or' connects the two drugs, indicating they are both being evaluated as primary treatments."", ""4. Classified both 'Idecabtagene Vicleucel' and 'Ciltacabtagene Autoleucel' as Primary Drugs based on the 'or' identifier."", ""5. Confirmed there are no secondary or comparator drugs mentioned."", ""6. Formatted the final JSON output according to the specified rules.""]",True,1
2983,,The Effects of Tranexamic Acid and Recombinant Activated Factor VII on Traumatic Bleeding and Mortality in Mice,,"[""Tranexamic Acid"", ""Recombinant Activated Factor VII""]",[],[],"[""1. Identified potential drug names in the title: 'Tranexamic Acid' and 'Recombinant Activated Factor VII'."", ""2. Analyzed the keyword 'and' connecting the two drug candidates."", ""3. According to the guidelines, the identifier 'and' indicates that both drugs are being studied as main therapeutic agents."", ""4. Classified both 'Tranexamic Acid' and 'Recombinant Activated Factor VII' as Primary drugs."", ""5. Confirmed no keywords for Secondary or Comparator drugs were present."", ""6. Formatted the final JSON output with the classified drugs and reasoning trace.""]",True,1
3344,,Real World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma,,"[""Axicabtagene Ciloleucel""]",[],"[""Lisocabtagene Maraleucel""]","[""Step 1: Analyzed the title to identify potential drug names and classification keywords."", ""Step 2: Identified 'Axicabtagene Ciloleucel' and 'Lisocabtagene Maraleucel' as candidate drugs."", ""Step 3: Identified the keyword phrase 'Comparison of... and...' which indicates a comparative study."", ""Step 4: Based on the guideline 'Comparing Drug A and Drug B -> Drug B = Comparator', classified the first drug, 'Axicabtagene Ciloleucel', as Primary."", ""Step 5: Classified the second drug, 'Lisocabtagene Maraleucel', as the Comparator."", ""Step 6: Formatted the final output into the required JSON structure with no secondary drugs identified.""]",True,1
3677,,Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide,,"[""Belantamab Mafodotin"", ""Pomalidomide"", ""Dexamethasone""]",[],"[""Pomalidomide"", ""Bortezomib"", ""Dexamethasone""]","[""1. Identified the keyword 'Vs' which separates the primary treatment arm from the comparator arm."", ""2. Extracted 'Belantamab Mafodotin', 'Pomalidomide', and 'Dexamethasone' from the first arm of the comparison."", ""3. The keywords 'Plus' and 'and' indicate these drugs are part of the primary regimen, so they were classified as Primary Drugs."", ""4. Extracted 'Pomalidomide', 'Bortezomib', and 'Dexamethasone' from the second arm following 'Vs'."", ""5. Classified the drugs in the second arm as Comparator Drugs."", ""6. Identified 'Lenalidomide' as a drug from a prior line of therapy and excluded it based on the exclusion rules."", ""7. Formatted the final JSON output with the classified drugs and reasoning trace.""]",True,1
564,,"Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) Results in Higher Remission Rates over Conventional 7+3 Chemotherapy without Increased Toxicity in Newly Diagnosed Acute Myeloid Leukemia",,"[""Venetoclax"", ""Cladribine"", ""Idarubicin"", ""Cytarabine""]",[],"[""7+3""]","[""1. Identified potential drug and regimen names: Venetoclax, Cladribine, Idarubicin, Cytarabine, CLIA, and 7+3 Chemotherapy."", ""2. The phrase 'Combined with' indicates that Venetoclax, Cladribine, Idarubicin, and Cytarabine are the primary therapeutic agents being studied together."", ""3. The keyword 'over' functions like 'versus', establishing '7+3 Chemotherapy' as the comparator arm."", ""4. Excluded the abbreviation 'CLIA' because its expanded drug names (Cladribine, Idarubicin, Cytarabine) are present in the title."", ""5. Classified Venetoclax, Cladribine, Idarubicin, and Cytarabine as Primary Drugs."", ""6. Classified the regimen '7+3' as a Comparator Drug, excluding the broad term 'Chemotherapy' as per exclusion rules."", ""7. Formatted the final JSON output.""]",True,1
876,,Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs,,"[""Tandem CAR-T-Cell Therapy Targeting CD5 and CD7"", ""Epitope-Edited Allogeneic Hematopoietic Stem Cell""]",[],[],"[""1. Identified potential therapeutic agents: 'Tandem CAR-T-Cell Therapy Targeting CD5 and CD7' and 'Epitope-Edited Allogeneic HSCs'."", ""2. Recognized both as cell-based therapies for inclusion per the guidelines."", ""3. Captured 'Tandem CAR-T-Cell Therapy Targeting CD5 and CD7' as a specific CAR-T variant."", ""4. Normalized 'Epitope-Edited Allogeneic HSCs' to 'Epitope-Edited Allogeneic Hematopoietic Stem Cell' by expanding the abbreviation 'HSCs' and applying the singular form rule for cell therapies."", ""5. The title describes a combined therapeutic strategy where the CAR-T therapy facilitates the engraftment of the HSCs, making both integral parts of the treatment. Therefore, both were classified as Primary."", ""6. Constructed the final JSON, leaving Secondary and Comparator arrays empty as no such drugs were mentioned.""]",True,1
4835,,"Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL",,"[""Allogeneic CD19/CD22-CAR T Cell"", ""Allogeneic Hematopoietic Cell""]",[],[],"[""1. Identified potential therapeutic agents: 'Allogeneic CD19/CD22-CAR T Cells' and 'Allo-HCT'."", ""2. Applied cell therapy inclusion rules, capturing 'Allogeneic CD19/CD22-CAR T Cell' as a specific CAR-T therapy and standardizing to the singular form."", ""3. Normalized the abbreviation 'Allo-HCT' to 'Allogeneic Hematopoietic Cell' per the stem cell therapy guidelines."", ""4. The keyword phrase 'Combination of... with...' indicates that both agents are part of the main therapeutic regimen being studied."", ""5. Classified 'Allogeneic CD19/CD22-CAR T Cell' and 'Allogeneic Hematopoietic Cell' as Primary Drugs."", ""6. Assembled the final JSON object with the extracted drugs and reasoning trace.""]",True,1
3429,,"ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs",,"[""Asciminib""]",[],[],"[""1. Scanned the title for potential drug names and classification keywords."", ""2. Identified 'Asciminib' as a specific drug name."", ""3. The phrase 'with Asciminib' indicates it is the therapeutic agent being studied in the real-world evidence arm."", ""4. The title compares a study (Ascembl) and real-world evidence, both involving Asciminib, making it the primary focus."", ""5. Identified 'TKIs' but excluded it as it refers to a broad drug class and a prior line of therapy ('Beyond 2 TKIs'), not a current treatment in the study."", ""6. Classified 'Asciminib' as a Primary Drug."", ""7. No secondary or comparator drugs were mentioned in the title."", ""8. Formatted the final JSON output.""]",True,1
3489,,Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up,,"[""Ibrutinib""]",[],[],"[""1. Analyzed the title for drug names and classification keywords."", ""2. Identified 'Ibrutinib' as the sole drug candidate mentioned."", ""3. The phrase 'Treatment with First-Line Ibrutinib' clearly indicates it is the primary therapeutic agent being studied."", ""4. Classified 'Ibrutinib' as a Primary Drug."", ""5. No other drugs were mentioned for combination, secondary use, or comparison, resulting in empty Secondary and Comparator drug lists."", ""6. Formatted the final output into the specified JSON structure.""]",True,1
4343,,Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia,,"[""Revumenib""]",[],[],"[""1. Analyzed the title for potential drug names and keywords."", ""2. Identified 'Revumenib' as the only drug candidate mentioned."", ""3. The title describes a study 'of Revumenib', indicating it is the main therapeutic agent under investigation."", ""4. Classified 'Revumenib' as a Primary drug."", ""5. No other drugs or classification keywords (e.g., 'vs', 'with or without') were present, so the Secondary and Comparator lists are empty."", ""6. Formatted the final output into the specified JSON structure.""]",True,1
4356,,Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia,,"[""Enzomenib"", ""DSP-5336""]",[],[],"[""1. Scanned the title for potential drug names and keywords."", ""2. Identified 'Enzomenib' and its code name '(DSP-5336)' as the therapeutic agents."", ""3. Excluded 'Menin-MLL Inhibitor' as it describes a mechanism of action, not a specific drug."", ""4. The phrase 'Study of... Enzomenib' indicates it is the sole drug being investigated."", ""5. Classified 'Enzomenib' and 'DSP-5336' as Primary Drugs."", ""6. Assembled the final JSON object with empty arrays for Secondary and Comparator categories.""]",True,1
4460,,Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study,,"[""Rituximab""]",[],[],"[""1. Scanned the title for drug names and classification keywords."", ""2. Identified 'Rituximab' as a drug candidate and 'Vs.' as a keyword."", ""3. Identified 'Watchful Waiting' as a non-drug management strategy and excluded it from extraction."", ""4. Analyzed the phrase 'Watchful Waiting Vs. Rituximab'. Since Rituximab is the active therapeutic agent being evaluated against a non-drug control, it is considered the primary drug under investigation."", ""5. Classified 'Rituximab' as a Primary drug."", ""6. Assembled the final JSON object with the classified drug and reasoning trace.""]",True,1
4461,,"Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from ""FOLL12"" Phase III Trial of the Fondazione Italiana Linfomi",,"[""Rituximab""]",[],[],"[""1. Scanned the title for potential drug names and classification keywords."", ""2. Identified 'Rituximab' as a drug candidate."", ""3. The context 'Rituximab Maintenance' indicates its use as a therapeutic agent."", ""4. No other drugs or keywords for comparison or secondary classification were present."", ""5. Classified 'Rituximab' as a Primary drug as it is the main therapy being discussed."", ""6. Constructed the final JSON object with the identified drug and empty arrays for the other categories.""]",True,1
4617,,"ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia",,"[""Mitapivat""]",[],[],"[""1. Scanned the title for potential drug names and identified 'Mitapivat' and 'Placebo'."", ""2. Applied the exclusion rule to 'Placebo', as it is a non-therapeutic control and must be excluded."", ""3. The title describes a 'Study of Mitapivat', indicating it is the main therapeutic agent under investigation."", ""4. Classified 'Mitapivat' as a Primary drug."", ""5. Constructed the final JSON object with the classified drug and empty arrays for the other categories.""]",True,1
4724,,Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial,,"[""Lacutamab""]",[],[],"[""1. Scanned the abstract title for potential drug names."", ""2. Identified 'Lacutamab' as a drug candidate."", ""3. The phrase 'Treated By Lacutamab' indicates it is the primary therapeutic agent being studied."", ""4. Classified Lacutamab as a Primary Drug."", ""5. No other drugs were mentioned, and no keywords for Secondary or Comparator drugs were present."", ""6. Formatted the final JSON output.""]",True,1
4751,,"Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)",,"[""Divesiran""]",[],[],"[""1. Scanned the title for potential drug names and identified 'Divesiran'."", ""2. The phrase 'Evaluating Divesiran' clearly indicates it is the primary drug under investigation."", ""3. Excluded 'Galnac Conjugated siRNA' as it is a description of the drug's technology/class, not a specific drug name."", ""4. Excluded 'SANRECO' as it is the name of the study, not a drug."", ""5. No keywords indicating secondary or comparator drugs were found."", ""6. Classified 'Divesiran' as a Primary Drug and left the other categories empty."", ""7. Formatted the final JSON output.""]",True,1
4866,,A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3,,"[""Ianalumab""]",[],[],"[""1. Scanned the title for drug names and identified 'Ianalumab'."", ""2. Analyzed the context, which describes a study focusing on a single drug, Ianalumab."", ""3. Classified 'Ianalumab' as a Primary drug because it is the sole therapeutic agent being evaluated in the study."", ""4. Noted the phrase 'Previously Treated with at Least Two Lines of Therapy' but excluded these unspecified prior treatments as per the exclusion rules."", ""5. Found no keywords indicating secondary or comparator drugs."", ""6. Assembled the final JSON with Ianalumab in the Primary Drugs list and empty lists for the other categories.""]",True,1
5173,,"HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30+ T Cell Lymphoma: Clinical Results of a Phase I/II Trial",,"[""HSP-CAR30""]",[],[],"[""1. Identified potential therapeutic agents in the title: 'HSP-CAR30' and 'CART30'."", ""2. Recognized that 'HSP-CAR30' is described as a specific type of 'CART30' ('HSP-CAR30, an Academic Memory-Enriched CART30')."", ""3. Applied the exclusion rule to capture only the specific drug ('HSP-CAR30') and exclude the broader drug class ('CART30')."", ""4. Classified 'HSP-CAR30' as a Primary drug because it is the main therapeutic agent being studied."", ""5. Confirmed there are no keywords indicating secondary or comparator drugs."", ""6. Constructed the final JSON object with the identified primary drug and empty arrays for other categories.""]",True,1
5613,,Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results,,"[""Iptacopan""]",[],[],"[""1. Identified the potential drug name 'Iptacopan' in the abstract title."", ""2. The term 'Monotherapy' indicates that Iptacopan is the single therapeutic agent being studied."", ""3. Based on the 'Monotherapy' keyword, Iptacopan is classified as a Primary Drug."", ""4. No other drugs or comparison keywords were found, so the Secondary and Comparator lists are empty."", ""5. Formatted the final output according to the specified JSON structure.""]",True,1
66,,"Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6",,"[""DISC-3405""]",[],[],"[""1. Analyzed the title to identify potential drug candidates."", ""2. Identified 'DISC-3405' as a specific drug name."", ""3. The phrase 'Recombinant Humanized Antibody Targeting TMPRSS6' is a description of the drug's class and mechanism of action, not a drug name, and is therefore excluded."", ""4. The study is explicitly 'of DISC-3405', making it the central focus and thus a Primary Drug."", ""5. No other drugs or comparison keywords are present, so the Secondary and Comparator lists are empty."", ""6. Formatted the final JSON output.""]",True,1
3323,,"Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials",,"[""Mini-CHOP"", ""Anti-CD20""]",[],[],"[""1. Identified potential therapeutic terms: 'Attenuated Chemotherapy', 'Mini-CHOP', and 'Anti-CD20'."", ""2. Excluded 'Attenuated Chemotherapy' as it is a broad therapy class per exclusion rules."", ""3. Identified 'Mini-CHOP' as a drug regimen and 'Anti-CD20' as a therapeutic agent for inclusion."", ""4. The keyword 'Plus' indicates that 'Mini-CHOP' and 'Anti-CD20' are co-administered as the primary treatment."", ""5. Classified 'Mini-CHOP' and 'Anti-CD20' as Primary Drugs."", ""6. No secondary or comparator drugs were identified in the title."", ""7. Formatted the final output into the required JSON structure.""]",True,1
2640,,Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study,,"[""R-GemOx""]",[],[],"[""1. Identified the potential drug regimen 'R-GemOx' from the abstract title."", ""2. The context 'Treated with R-GemOx' indicates its use as a therapeutic agent for the disease."", ""3. According to the inclusion rules, abbreviated regimens are captured when their expanded form is not present in the title."", ""4. As 'R-GemOx' is the sole treatment regimen being evaluated, it is classified as a Primary Drug."", ""5. Formatted the final output into the specified JSON structure, with empty arrays for the other categories.""]",True,1
1356,,Split-Dose R-CHOP for Older Patients with Treatment Naive DLBCL,,"[""R-CHOP""]",[],[],"[""1. Identified the term 'R-CHOP' as a potential drug regimen from the title."", ""2. The expanded form of the regimen is not present, so the abbreviation 'R-CHOP' is captured per inclusion rules."", ""3. 'R-CHOP' is the sole therapeutic agent mentioned as the focus of the study."", ""4. Classified 'R-CHOP' as a Primary Drug."", ""5. Constructed the final JSON object with the extracted drug and reasoning trace.""]",True,1
1208,,Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy,,"[""CAR-T Cell""]",[],[],"[""1. Identified 'CAR-T Therapy' as a potential therapeutic agent in the title."", ""2. Applied the inclusion rules for cell therapies, which specify capturing CAR-T."", ""3. Normalized 'CAR-T Therapy' to 'CAR-T Cell' as per the specific formatting guidelines."", ""4. Classified 'CAR-T Cell' as a Primary drug as it is the central therapy being discussed."", ""5. No other drugs were mentioned for Secondary or Comparator classification."", ""6. Formatted the final output into the required JSON structure.""]",True,1
3863,,Preclinical Efficacy of Decoy-Resistant IL-18 in Hematological Malignancies,,"[""Decoy-Resistant IL-18""]",[],[],"[""1. Analyzed the title to identify potential therapeutic agents."", ""2. Identified 'Decoy-Resistant IL-18' as a laboratory-produced compound being evaluated for its efficacy."", ""3. Classified 'Decoy-Resistant IL-18' as a Primary drug as it is the sole agent under investigation in the title."", ""4. Confirmed there are no other drugs mentioned to be classified as Secondary or Comparator."", ""5. Formatted the output into the specified JSON structure.""]",True,1
2663,,Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma,,[],[],[],"[""1. Scanned the title for potential drug names."", ""2. Identified '18FDG' as a candidate, which is a diagnostic agent."", ""3. Analyzed the context of '18FDG'. The title states its use in a PET/CT scan to predict prognosis, which is a diagnostic, not a therapeutic, application."", ""4. Based on the objective to only extract drugs for 'therapeutic use', '18FDG' was excluded."", ""5. No other therapeutic drugs or regimens were identified in the title."", ""6. Finalized the output with empty arrays for all drug categories.""]",True,1
686,,"The Effectiveness of Levofloxacin in Prevention of Febrile Episodes in Non-Hodgkin Lymphoma Patients Receiving Rituximab, Cyclophosphamide, Vincristine, Doxorubicin and Prednisolone (R-CHOP)",,"[""Levofloxacin"", ""Rituximab"", ""Cyclophosphamide"", ""Vincristine"", ""Doxorubicin"", ""Prednisolone""]",[],[],"[""1. Scanned the title to identify potential drug names and regimens."", ""2. Identified 'Levofloxacin', 'Rituximab', 'Cyclophosphamide', 'Vincristine', 'Doxorubicin', 'Prednisolone', and the regimen 'R-CHOP'."", ""3. Applied the exclusion rule to prefer expanded drug names over the abbreviation, so 'R-CHOP' was excluded as its components were listed."", ""4. Analyzed the drug roles: 'Levofloxacin' is the drug being evaluated, and the other drugs are the background therapeutic regimen."", ""5. As all drugs are administered for therapeutic use and no keywords indicate a secondary or comparator role, all were classified as Primary."", ""6. Formatted the final drug list into the specified JSON structure.""]",True,1
661,,"Combination of Mitoxantrone Hydrochloride Liposome with Gemcitabine, Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A Phase I Study",,"[""Mitoxantrone Hydrochloride Liposome"", ""Gemcitabine"", ""Cisplatin"", ""Dexamethasone""]",[],[],"[""Step 1: Identified potential drug names from the title: Mitoxantrone Hydrochloride Liposome, Gemcitabine, Cisplatin, and Dexamethasone."", ""Step 2: Analyzed the keywords 'Combination of', 'with', and 'and' to understand the relationship between the drugs."", ""Step 3: The keywords indicate that all drugs are being administered together as the main therapeutic regimen under investigation."", ""Step 4: Classified Mitoxantrone Hydrochloride Liposome, Gemcitabine, Cisplatin, and Dexamethasone as Primary Drugs."", ""Step 5: No keywords suggesting secondary or comparator drugs were present in the title."", ""Step 6: Assembled the final JSON object with the classified drugs and the reasoning trace.""]",True,1
2339,,"Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP+-R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis",,"[""Cyclophosphamide"", ""Mitoxantrone Hydrochloride Liposome"", ""Vincristine"", ""Prednisone""]","[""Rituximab""]",[],"[""1. Identified potential drug names: Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, Prednisone, and Rituximab."", ""2. The phrase 'Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone' uses commas and the conjunction 'and', indicating these are the core components of the primary treatment regimen."", ""3. Classified Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone as Primary Drugs."", ""4. The identifier 'with or without' precedes Rituximab, which classifies it as a Secondary Drug based on the provided guidelines."", ""5. Excluded the abbreviated regimen 'CMOP+-R' because its full components were already identified and captured."", ""6. No comparator drugs were identified in the title."", ""7. Formatted the final drug lists and constructed the JSON output.""]",True,1
335,,"Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia",,"[""Hyper-CVAD"", ""Blinatumomab""]","[""Inotuzumab Ozogamicin""]",[],"[""1. Identified potential drug and regimen names from the title: Hyper-CVAD, Inotuzumab Ozogamicin, and Blinatumomab."", ""2. Analyzed the connecting phrases. The phrase 'with or without' links Hyper-CVAD and Inotuzumab Ozogamicin."", ""3. The phrase 'and Sequential' links Blinatumomab to the core treatment regimen."", ""4. Classified Hyper-CVAD and Blinatumomab as Primary drugs as they form the main therapeutic regimen being studied."", ""5. Classified Inotuzumab Ozogamicin as a Secondary drug based on the specific identifier 'with or without'."", ""6. Confirmed there are no comparator drugs mentioned in the title."", ""7. Formatted the extracted drugs into the final JSON output.""]",True,1
706,,"The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma",,"[""Rituximab"", ""Methotrexate"", ""Thiotepa"", ""Orelabrutinib"", ""Autologous Stem Cell""]",[],[],"[""1. Identified potential drug and therapy terms: R-MTO Regimen, Rituximab, Methotrexate, Thiotepa, Orelabrutinib, and Autologous Stem Cell Transplantation."", ""2. Excluded the abbreviated regimen 'R-MTO' because its full components (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) are explicitly listed."", ""3. Normalized 'Autologous Stem Cell Transplantation' to 'Autologous Stem Cell' per the cell therapy mapping rules."", ""4. Classified Rituximab, Methotrexate, Thiotepa, and Orelabrutinib as Primary because they are part of the main induction therapy regimen."", ""5. The keyword 'Followed By' indicates that Autologous Stem Cell is also a core part of the treatment plan, thus classifying it as Primary."", ""6. No keywords indicating Secondary or Comparator drugs were found."", ""7. Assembled the final JSON object with the classified drugs and reasoning trace.""]",True,1
2076,,"Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group",,"[""Isatuximab"", ""Bortezomib"", ""Cyclophosphamide"", ""Dexamethasone"", ""Lenalidomide""]",[],[],"[""1. Identified potential drug names from the title: Isatuximab, Bortezomib, Cyclophosphamide, Dexamethasone, and Lenalidomide."", ""2. The phrase 'in Combination with' indicates that Isatuximab, Bortezomib, Cyclophosphamide, and Dexamethasone are part of the primary treatment regimen."", ""3. The phrase 'Followed By' indicates that the subsequent Isatuximab and Lenalidomide maintenance therapy is also a core component of the studied treatment."", ""4. All identified drugs are part of the single therapeutic strategy being evaluated, classifying them all as Primary."", ""5. No keywords indicating Secondary or Comparator drugs (e.g., 'vs', 'with or without') were found."", ""6. Formatted the final JSON output, placing all drugs in the 'Primary Drugs' list and leaving the other categories empty.""]",True,1
4684,,"Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study",,"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]","[""Daratumumab""]",[],"[""1. Identified potential drug names from the title: Bortezomib, Lenalidomide, Dexamethasone, and Daratumumab."", ""2. Analyzed the phrase 'Bortezomib, Lenalidomide and Dexamethasone'. The keyword 'and' indicates these are core components of the primary treatment regimen."", ""3. Classified Bortezomib, Lenalidomide, and Dexamethasone as Primary Drugs."", ""4. Analyzed the phrase 'with or without Daratumumab'. The identifier 'with or without' explicitly defines Daratumumab as an optional, add-on therapy."", ""5. Classified Daratumumab as a Secondary Drug."", ""6. Confirmed the maintenance phase description ('Lenalidomide with or without Daratumumab') reinforces the classification of Lenalidomide as Primary and Daratumumab as Secondary."", ""7. No comparator keywords such as 'vs' or 'compared to' were present, so the Comparator Drugs list is empty."", ""8. Assembled the final JSON object with the classified drugs and reasoning trace.""]",True,1
691,,"Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma",,"[""Zanubrutinib"", ""Rituximab"", ""Methotrexate""]",[],[],"[""1. Identified potential drug names from the title: Zanubrutinib, Rituximab, and Methotrexate."", ""2. Analyzed the keywords 'in Combination with', 'and', and 'Followed By' to understand the relationship between the drugs."", ""3. The phrase 'Zanubrutinib in Combination with Rituximab and Methotrexate' indicates these three drugs are administered together as a primary treatment."", ""4. The phrase 'Followed By Zanubrutinib Maintenance' confirms Zanubrutinib's role as a primary agent throughout the study."", ""5. Classified Zanubrutinib, Rituximab, and Methotrexate as Primary drugs."", ""6. No keywords suggesting Secondary or Comparator drugs were present in the title."", ""7. Assembled the final JSON object with the classified drugs and reasoning trace.""]",True,1
337,,"Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update",,"[""Mini-Hypercvd"", ""Inotuzumab Ozogamicin""]","[""Blinatumomab""]",[],"[""1. Identified potential drug and regimen names: Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino), and Blinatumomab (Blina)."", ""2. Used the full names provided and excluded the abbreviations in parentheses as per inclusion rules."", ""3. Analyzed the connecting phrases. The comma between 'Mini-Hypercvd' and 'Inotuzumab Ozogamicin' indicates they are part of the core treatment regimen, classifying them as Primary."", ""4. The identifier 'with/without' precedes 'Blinatumomab', which classifies it as a Secondary drug according to the guidelines."", ""5. No comparator drugs were identified."", ""6. Formatted the final JSON output with the classified drugs and reasoning steps.""]",True,1
2505,,"A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome",,"[""Azacitidine"", ""Ipilimumab"", ""Nivolumab""]",[],[],"[""1. Identified drug candidates from the title: Azacitidine, Ipilimumab, and Nivolumab."", ""2. Analyzed the title structure which describes multiple treatment arms."", ""3. The phrase 'Azacitidine with Ipilimumab, Nivolumab' and 'Ipilimumab and Nivolumab' use keywords ('with', 'or', 'and') that designate Primary drugs, establishing Azacitidine, Ipilimumab, and Nivolumab as primary agents."", ""4. The phrase 'with or without Azacitidine' uses a keyword that typically indicates a Secondary drug."", ""5. Since Azacitidine is presented in both a primary context ('Azacitidine with...') and a secondary context ('with or without Azacitidine'), its role as a main therapeutic agent being studied takes precedence."", ""6. All three drugs are central to the combinations being evaluated in the trial and are therefore classified as Primary."", ""7. No comparator keywords (e.g., 'vs', 'compared to') were found, so the Comparator Drugs list is empty."", ""8. Formatted the final output into the specified JSON structure.""]",True,1
3338,,"Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma",,"[""Orelabrutinib"", ""Rituximab"", ""Thiotepa""]","[""Methotrexate""]",[],"[""1. Identified potential drug names: Orelabrutinib, Rituximab, Thiotepa, ORT, and High-Dose Methotrexate."", ""2. Analyzed keywords: The phrase 'and' and 'in Combination with' indicate Orelabrutinib, Rituximab, and Thiotepa are the core treatment."", ""3. Classified Orelabrutinib, Rituximab, and Thiotepa as Primary Drugs."", ""4. The keyword phrase 'with or without' clearly identifies Methotrexate as a Secondary Drug."", ""5. Excluded the regimen abbreviation 'ORT' as the full drug names were provided."", ""6. Removed dosage information 'High-Dose' from Methotrexate per exclusion rules."", ""7. No comparator drugs were identified based on keywords like 'vs' or 'compared to'."", ""8. Formatted the final output into the specified JSON structure.""]",True,1
3705,,Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM),,"[""Personalized Neoantigen Peptide Vaccine""]","[""Lenalidomide""]",[],"[""1. Identified potential therapeutic agents: 'Personalized Neoantigen Peptide Vaccine' and 'Lenalidomide'."", ""2. Analyzed the keyword 'with or without' connecting the two agents."", ""3. Based on the rule 'Drug A with or without Drug B', 'Personalized Neoantigen Peptide Vaccine' (Drug A) is classified as Primary."", ""4. Following the same rule, 'Lenalidomide' (Drug B) is classified as Secondary."", ""5. No comparator keywords like 'vs' or 'compared to' were found, so the Comparator Drugs list is empty."", ""6. Formatted the final output according to the specified JSON structure.""]",True,1
4980,,"Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial",,"[""Acalabrutinib"", ""Venetoclax""]","[""Obinutuzumab""]",[],"[""1. Identified potential drug and therapy terms: Acalabrutinib, Venetoclax, Obinutuzumab, and Chemoimmunotherapy."", ""2. Analyzed the phrase 'Acalabrutinib Plus Venetoclax'. The keyword 'Plus' indicates that Acalabrutinib and Venetoclax are co-administered as primary treatments."", ""3. Classified Acalabrutinib and Venetoclax as Primary Drugs."", ""4. Analyzed the phrase 'with or without Obinutuzumab'. The identifier 'with or without' indicates that Obinutuzumab is an optional, add-on therapy."", ""5. Classified Obinutuzumab as a Secondary Drug."", ""6. Identified 'Chemoimmunotherapy' as the comparator arm based on the keyword 'Versus'."", ""7. Excluded 'Chemoimmunotherapy' from the Comparator Drugs list because it is a broad therapy class, not a specific drug, as per the exclusion rules."", ""8. Formatted the final output into the specified JSON structure.""]",True,1
2232,,"Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial",,"[""Daunorubicin"", ""Cytarabine""]","[""Cladribine""]",[],"[""1. Identified the treatment regimen '(DA +/- cladribine)' in the title."", ""2. Expanded the regimen abbreviation 'DA' to its constituent drugs, Daunorubicin and Cytarabine, which are commonly used for AML."", ""3. Identified the keyword '+/-' (plus/minus), which indicates an optional, secondary drug."", ""4. Classified the base regimen drugs, Daunorubicin and Cytarabine, as Primary Drugs."", ""5. Classified 'Cladribine' as a Secondary Drug because it follows the '+/-' identifier."", ""6. No comparator drugs were mentioned in the title."", ""7. Formatted the final drug list into the specified JSON structure.""]",True,1
1209,,Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone,,"[""Axicabtagene Ciloleucel""]","[""Dexamethasone""]",[],"[""1. Identified potential drug names from the title: 'Axicabtagene Ciloleucel' and 'Dexamethasone'."", ""2. Analyzed the connecting phrase 'with or without' to determine the relationship between the drugs."", ""3. Classified 'Axicabtagene Ciloleucel' as the main therapy being studied, making it a Primary Drug."", ""4. The identifier 'with or without' indicates that 'Dexamethasone' is an optional addition, classifying it as a Secondary Drug according to the guidelines."", ""5. No comparator drugs were identified in the title."", ""6. Assembled the final JSON object with the classified drugs and reasoning trace.""]",True,1
514,,Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab,,"[""Crovalimab""]",[],[],"[""1. Identified potential drug names in the title: Crovalimab and Eculizumab."", ""2. Analyzed the context of each drug."", ""3. Classified Crovalimab as the Primary drug because its safety and efficacy are the focus of the trial."", ""4. Excluded Eculizumab because it is mentioned as a prior therapy from which patients switched, not as a treatment being evaluated in this study, according to exclusion rules."", ""5. Assembled the final JSON object with the classified drug and empty arrays for the other categories.""]",True,1
987,,A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma,,"[""CD19 CAR T-Cell""]","[""Rituximab""]",[],"[""1. Identified potential therapeutic agents from the title: 'CD19 CAR T-Cells' and 'Rituximab'."", ""2. Excluded 'Lymphodepletion' as it is a general therapeutic procedure, not a specific drug."", ""3. Classified 'CD19 CAR T-Cell' as a Primary drug as it is the main therapy under investigation."", ""4. Identified the keyword phrase 'with or without' preceding 'Rituximab'."", ""5. Based on the 'with or without' identifier, classified 'Rituximab' as a Secondary drug."", ""6. No comparator keywords were found, resulting in an empty Comparator Drugs list."", ""7. Formatted the output according to the specified JSON structure, including singularizing 'CD19 CAR T-Cells' to 'CD19 CAR T-Cell' per cell therapy rules.""]",True,1
1743,,"Preliminary Data of a Single-Arm, Phase II Study of Orelabrutinib with/without Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma after BTK Inhibitor Therapy",,"[""Orelabrutinib""]","[""Rituximab""]",[],"[""1. Identified potential drug names from the title: 'Orelabrutinib' and 'Rituximab'."", ""2. Identified the keyword phrase 'with/without' connecting the two drugs."", ""3. Based on the guideline 'Drug A with or without Drug B', 'Drug A' (Orelabrutinib) is classified as Primary."", ""4. Following the same guideline, 'Drug B' (Rituximab) is classified as Secondary."", ""5. Excluded 'BTK Inhibitor Therapy' as it refers to a prior treatment and a drug class, not a specific drug under investigation in this study."", ""6. Confirmed there are no comparator drugs mentioned."", ""7. Assembled the final JSON object with the classified drugs.""]",True,1
4283,,"Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study",,"[""Motixafortide"", ""Natalizumab"", ""Hematopoietic Stem Cell""]",[],[],"[""1. Identified drug and therapy candidates from the title: 'Motixafortide', 'CXCR4 Inhibition', 'Natalizumab', 'VLA-4 Inhibition', and 'Hematopoietic Stem Cells'."", ""2. Excluded 'CXCR4 Inhibition' and 'VLA-4 Inhibition' as they are mechanisms of action, not drugs."", ""3. Analyzed the keyword phrase 'Alone and in Combination with', which indicates that the associated drugs are co-primary."", ""4. Classified 'Motixafortide' and 'Natalizumab' as Primary drugs based on the identifier."", ""5. Identified 'Hematopoietic Stem Cells' as a cell therapy component of the novel regimen. Captured it as 'Hematopoietic Stem Cell' (singular form) and classified it as Primary."", ""6. Assembled the final JSON, ensuring correct formatting and including empty arrays for categories with no drugs.""]",True,1
3964,,Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data,,"[""Olutasidenib""]","[""Azacitidine""]",[],"[""1. Identified drug candidates from the title: Olutasidenib and Azacitidine."", ""2. Analyzed the connecting phrase 'Alone or in Combination with' to determine the relationship between the drugs."", ""3. According to the classification guidelines, the structure 'Drug A alone or in combination with Drug B' designates Drug A as Primary and Drug B as Secondary."", ""4. Classified Olutasidenib as a Primary Drug."", ""5. Classified Azacitidine as a Secondary Drug."", ""6. Formatted the final output into the specified JSON structure.""]",True,1
560,,"Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up",,"[""Gemtuzumab Ozogamicin"", ""Fludarabine"", ""Cytarabine"", ""G-CSF""]",[],"[""Idarubicin""]","[""1. Identified potential drug names and regimens: Gemtuzumab Ozogamicin, Fludarabine, Cytarabine, G-CSF, FLAG-GO, Idarubicin, and FLAG-IDA."", ""2. Analyzed the phrase 'Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF'. The keyword 'Added to' indicates these are all part of the primary therapeutic regimen."", ""3. Classified Gemtuzumab Ozogamicin, Fludarabine, Cytarabine, and G-CSF as Primary Drugs."", ""4. Excluded the regimen abbreviation 'FLAG-GO' because its individual components are explicitly listed, per exclusion rules."", ""5. Analyzed the phrase '...Superior... Than Idarubicin (FLAG-IDA)'. The keyword 'Than' indicates a comparison."", ""6. Classified Idarubicin as the Comparator Drug."", ""7. Excluded the regimen abbreviation 'FLAG-IDA' as the specific drug component being compared (Idarubicin) is explicitly mentioned."", ""8. Formatted the final lists and constructed the JSON output.""]",True,1
6012,,"SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)",,"[""Glofitamab"", ""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]",[],"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]","[""1. Identified potential drug candidates: Glofitamab, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, and the regimen Pola-R-CHP."", ""2. Analyzed the structure 'A Plus B Versus C', where A is Glofitamab and B and C are the Pola-R-CHP regimen."", ""3. The keyword 'Plus' indicates the experimental arm consists of Glofitamab combined with the components of Pola-R-CHP. These are all classified as Primary Drugs."", ""4. The keyword 'Versus' identifies the comparator arm, which is the Pola-R-CHP regimen."", ""5. The individual drugs within the comparator regimen (Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone) are classified as Comparator Drugs."", ""6. Excluded the abbreviated regimen 'Pola-R-CHP' from the final lists because its expanded form is provided, as per exclusion rules."", ""7. Formatted the final drug lists into the specified JSON structure.""]",True,1
569,,Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center,,"[""FLAG-Idarubicin"", ""Venetoclax""]",[],[],"[""1. Identified drug and regimen candidates from the title: 'FLAG-Idarubicin' and 'Venetoclax'."", ""2. Analyzed the structure 'Comparison of A to B', where A is 'FLAG-Idarubicin' and B is 'FLAG-Idarubicin Plus Venetoclax'. This indicates a comparator relationship."", ""3. The experimental arm is 'FLAG-Idarubicin Plus Venetoclax', and the control arm is 'FLAG-Idarubicin'."", ""4. Based on the 'Plus' keyword in the experimental arm, both 'FLAG-Idarubicin' and 'Venetoclax' are initially identified as Primary drugs."", ""5. The drug in the control arm, 'FLAG-Idarubicin', is initially identified as a Comparator drug."", ""6. A conflict exists as 'FLAG-Idarubicin' is present in both the primary experimental arm and the comparator arm."", ""7. To resolve the conflict, the drug's role in the primary experimental arm is prioritized. Therefore, 'FLAG-Idarubicin' is classified as a Primary drug, and it is not listed as a Comparator to avoid duplication."", ""8. The final classification is 'FLAG-Idarubicin' and 'Venetoclax' as Primary Drugs, with no drugs in the Comparator or Secondary categories.""]",True,1
6089,,"Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma",,"[""Genotype-Guided Targeted Agents"", ""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]",[],"[""Pola-Rchp""]","[""1. Identified potential drug names and regimens: Genotype-Guided Targeted Agents, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, POLA-RCHP-X, and Pola-Rchp."", ""2. Analyzed the phrase 'in Combination with' which links 'Genotype-Guided Targeted Agents' with the listed drugs, classifying them all as Primary."", ""3. Excluded the regimen abbreviation 'POLA-RCHP-X' because its full components are explicitly listed in the title, as per exclusion rules."", ""4. Identified the keyword 'Versus', which designates 'Pola-Rchp' as the comparator arm."", ""5. Classified 'Genotype-Guided Targeted Agents', 'Polatuzumab Vedotin', 'Rituximab', 'Cyclophosphamide', 'Doxorubicin', and 'Prednisone' as Primary Drugs."", ""6. Classified 'Pola-Rchp' as a Comparator Drug."", ""7. Confirmed there are no keywords indicating Secondary drugs, leaving the array empty."", ""8. Assembled the final JSON object with the classified drugs and reasoning trace.""]",True,1
1305,,Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma,,"[""EPOCH""]",[],"[""DCEP""]","[""1. Identified potential drug regimens 'EPOCH' and 'DCEP' from the title."", ""2. Analyzed the keyword 'Comparison of', which indicates a comparative study."", ""3. The structure 'Comparison of... (EPOCH and DCEP)' implies EPOCH is being compared against DCEP."", ""4. Based on the guideline 'Comparing Drug A and Drug B -> Drug B = Comparator', classified EPOCH as Primary and DCEP as Comparator."", ""5. Confirmed that abbreviated regimens should be captured as their expanded forms are not present in the title."", ""6. Assembled the final JSON object with the classified regimens and the reasoning trace.""]",True,1
1216,,"Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Allogeneic Stem Cell Transplantation Demonstrates Improved Overall Survival and Reduced Mortality, Shorter Length of Stay, Less Peritransplant Toxicity with Post-Transplant Cyclophosphamide",,"[""Cyclophosphamide""]",[],"[""Tacrolimus"", ""Methotrexate""]","[""1. Identified potential drug candidates: Tacrolimus, Methotrexate, and Post-Transplant Cyclophosphamide."", ""2. Analyzed the title structure: 'Comparison of [A] and [B]... demonstrates improved... with [B]'. This indicates that regimen B (Post-Transplant Cyclophosphamide) is the primary focus of the study, and regimen A (Tacrolimus/Methotrexate) is the comparator."", ""3. Classified 'Cyclophosphamide' as the Primary drug, extracting the drug name from 'Post-Transplant Cyclophosphamide'."", ""4. Classified 'Tacrolimus' and 'Methotrexate' as Comparator drugs, as they form the regimen being compared against."", ""5. The '/' between Tacrolimus and Methotrexate indicates they are part of the same comparator arm."", ""6. Excluded 'Allogeneic Stem Cell Transplantation' as it is the background procedure for which the drug regimens are being administered as prophylaxis, not a drug being compared in this context."", ""7. Formatted the final JSON output.""]",True,1
1217,,Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Espanol De Trasplante y Terapia Celular (GETH-TC),,"[""Treosulfan"", ""Fludarabine"", ""Allogeneic Hematopoietic Cell""]",[],"[""Thiotepa"", ""Busulfan"", ""Fludarabine""]","[""1. Identified drug candidates: Treosulfan, Fludarabine, Thiotepa, Busulfan, and the cell therapy 'Allogeneic Hematopoietic Cell Transplantation'."", ""2. Normalized 'Allogeneic Hematopoietic Cell Transplantation' to 'Allogeneic Hematopoietic Cell' according to the cell therapy inclusion rules."", ""3. Detected the keyword 'Versus', which establishes a comparison between two treatment regimens."", ""4. Classified the regimen before 'Versus' (Treosulfan/Fludarabine) and the common cell therapy as Primary."", ""5. Classified the regimen after 'Versus' (Thiotepa/Busulfan/Fludarabine) as Comparator."", ""6. Formatted the extracted drugs into the final JSON structure with no secondary drugs identified.""]",True,1
3780,,High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI),,"[""Isatuximab"", ""Lenalidomide"", ""Dexamethasone"", ""Bortezomib""]",[],"[""Isard""]","[""1. Identified potential drug and regimen names: Isatuximab (Isa), Lenalidomide, Dexamethasone (Rd), Bortezomib, and Isard."", ""2. Analyzed keywords: 'Plus' and 'with' indicate a primary combination therapy. 'Versus' indicates a comparator."", ""3. Classified the combination of Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib as Primary Drugs."", ""4. Classified the regimen 'Isard' as a Comparator Drug based on the keyword 'Versus'."", ""5. Excluded the abbreviations 'Isa' and 'Rd' because their expanded forms are present in the title."", ""6. Formatted the final drug lists into the specified JSON structure.""]",True,1
2691,,"Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study",,"[""Isatuximab"", ""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]",[],"[""Vrd""]","[""1. Identified drug candidates: Isatuximab, Bortezomib, Lenalidomide, Dexamethasone, and the regimens Isa-VRd and Vrd."", ""2. Analyzed the title structure, which compares the 'Isa-VRd' regimen against the 'Vrd' regimen using the keyword 'Vs.'."", ""3. Classified Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone as Primary drugs, as they form the main study arm."", ""4. Excluded the abbreviation 'Isa-VRd' because its expanded drug names are present in the title, following the exclusion rules."", ""5. Classified 'Vrd' as the Comparator, as it is the regimen being compared against."", ""6. Formatted the final JSON output, ensuring no secondary drugs were identified.""]",True,1
4934,,"Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial",,"[""Belantamab Mafodotin"", ""Bortezomib"", ""Dexamethasone""]",[],"[""Daratumumab"", ""Bortezomib"", ""Dexamethasone""]","[""1. Identified potential drug names: Belantamab Mafodotin, Bortezomib, Dexamethasone, and Daratumumab."", ""2. Analyzed the keyword 'Vs' which separates the primary treatment arm from the comparator arm."", ""3. The regimen 'Belantamab Mafodotin, Bortezomib, and Dexamethasone' precedes 'Vs', classifying these drugs as Primary."", ""4. The regimen 'Daratumumab, Bortezomib, and Dexamethasone' follows 'Vs', classifying these drugs as Comparator."", ""5. Confirmed no keywords indicating Secondary drugs are present."", ""6. Formatted the extracted drug names and constructed the final JSON output.""]",True,1
659,,Comparison of Efficacy and Safety of Gdpt and CHOP in First-Line Treatment of Peripheral T-Cell Lymphoma,,"[""Gdpt""]",[],"[""CHOP""]","[""1. Identified potential drug regimens 'Gdpt' and 'CHOP' from the title."", ""2. Analyzed the keyword 'Comparison of' which indicates a comparative study between the two regimens."", ""3. Classified 'Gdpt' as the Primary drug regimen being evaluated."", ""4. Classified 'CHOP' as the Comparator regimen based on the comparative context."", ""5. Both terms are abbreviated regimens and are included as their expanded forms are not provided."", ""6. Assembled the final JSON output with the classified drugs and reasoning trace.""]",True,1
2074,,"Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial",,"[""Belantamab Mafodotin"", ""Bortezomib"", ""Dexamethasone""]",[],"[""Daratumumab"", ""Bortezomib"", ""Dexamethasone""]","[""1. Identified potential drug names from the title: Belantamab Mafodotin, Bortezomib, Dexamethasone, and Daratumumab."", ""2. Detected the keyword 'Vs' which separates the primary treatment arm from the comparator arm."", ""3. The regimen 'Belantamab Mafodotin Plus Bortezomib and Dexamethasone' is the primary treatment being studied, as it appears before 'Vs'."", ""4. The keywords 'Plus' and 'and' indicate co-administration, leading to the classification of Belantamab Mafodotin, Bortezomib, and Dexamethasone as Primary Drugs."", ""5. The regimen 'Daratumumab, Bortezomib, and Dexamethasone' follows 'Vs', identifying it as the comparator arm."", ""6. Classified Daratumumab, Bortezomib, and Dexamethasone as Comparator Drugs."", ""7. No keywords such as 'with or without' were found, so the Secondary Drugs list is empty."", ""8. Formatted the final JSON output according to the specified rules.""]",True,1
4668,,PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601,,"[""ABVD""]",[],"[""Bv"", ""AVD"", ""Nivolumab""]","[""1. Identified potential drug and regimen candidates from the title: ABVD, Bv, AVD, and Nivolumab."", ""2. Analyzed the title structure, noting the keyword 'Vs.' which indicates a comparison between two distinct treatment arms."", ""3. Applied the rule 'Drug A vs Drug B -> Drug B = Comparator', which designates the first arm ('ABVD') as the primary treatment being studied."", ""4. Classified 'ABVD' as a Primary drug."", ""5. Identified the second arm ('Bv+AVD Followed By Nivolumab') as the comparator."", ""6. Extracted the individual components of the comparator arm, linked by '+' and 'Followed By': 'Bv', 'AVD', and 'Nivolumab'."", ""7. Classified 'Bv', 'AVD', and 'Nivolumab' as Comparator drugs."", ""8. Assembled the final JSON, ensuring correct formatting and placing drugs in their respective categories.""]",True,1
4822,,Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma,,"[""Carfilzomib"", ""Lenalidomide"", ""Dexamethasone""]",[],"[""Lenalidomide"", ""Dexamethasone""]","[""1. Identified drug candidates from the title: Carfilzomib, Lenalidomide, and Dexamethasone, which form two distinct regimens."", ""2. Detected the keyword 'Vs' (versus), indicating a comparison between two treatment arms."", ""3. The regimen 'Carfilzomib-Lenalidomide-Dexamethasone' precedes 'Vs', classifying its components (Carfilzomib, Lenalidomide, Dexamethasone) as Primary."", ""4. The regimen 'Lenalidomide-Dexamethasone' follows 'Vs', classifying its components (Lenalidomide, Dexamethasone) as Comparator."", ""5. No keywords indicating secondary drugs were found."", ""6. Assembled the final JSON object with the classified drugs and reasoning trace.""]",True,1
1041,,"Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study",,"[""Daratumumab"", ""Pomalidomide"", ""Dexamethasone""]",[],"[""Daratumumab"", ""Carfilzomib"", ""Dexamethasone""]","[""1. Analyzed the title to identify potential drug names and classification keywords."", ""2. Identified two distinct drug regimens: (Daratumumab, Pomalidomide and Dexamethasone) and (Daratumumab, Carfilzomib and Dexamethasone)."", ""3. The keyword 'Compared to' indicates a comparison between the two regimens."", ""4. The first regimen (Daratumumab, Pomalidomide, Dexamethasone) is classified as Primary, as it is the subject of the comparison."", ""5. The second regimen (Daratumumab, Carfilzomib, Dexamethasone) is classified as Comparator, as it is the treatment being compared against."", ""6. No secondary drugs were identified based on keywords like 'with or without'."", ""7. Formatted the final list of drugs into the specified JSON structure.""]",True,1
6067,,A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209,,"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]",[],"[""Daratumumab"", ""Lenalidomide"", ""Dexamethasone""]","[""1. Identified drug candidates: Bortezomib, Lenalidomide, Dexamethasone, VRd-Lite, Len, Daratumumab, DRd, Dara."", ""2. The keyword 'Comparing' establishes a primary arm and a comparator arm."", ""3. The first regimen, 'Bortezomib-Lenalidomide-Dexamethasone', is identified as the primary arm. Its components are classified as Primary Drugs."", ""4. The second regimen, 'Daratumumab-Lenalidomide-Dexamethasone', is identified as the comparator arm. Its components are classified as Comparator Drugs."", ""5. The abbreviations (VRd-Lite, Len, DRd, Dara) are excluded because their full drug names are provided in the title."", ""6. The '+/-' symbol applies to 'Dara' within the maintenance phase of the comparator arm, so Daratumumab's classification remains as a Comparator based on the main trial comparison."", ""7. Formatted the final drug lists and constructed the JSON output.""]",True,1
1758,,Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia,,"[""Haploidentical Hematopoietic Stem Cell"", ""Eltrombopag""]",[],[],"[""1. Identified potential therapeutic agents: 'Haploidentical Hematopoietic Stem Cell Transplantation', 'Eltrombopag', and 'Standard Immunosuppression'."", ""2. Applied cell therapy normalization rules: 'Haploidentical Hematopoietic Stem Cell Transplantation' was captured as 'Haploidentical Hematopoietic Stem Cell' by removing the procedural term 'Transplantation'."", ""3. Applied exclusion rules: 'Standard Immunosuppression' was excluded as it is a broad therapy class."", ""4. Analyzed the keyword 'Comparisons between'. This structure indicates that the two arms ('Haploidentical Hematopoietic Stem Cell' and 'Eltrombopag') are the primary subjects of the study being compared against each other."", ""5. Classified both 'Haploidentical Hematopoietic Stem Cell' and 'Eltrombopag' as Primary."", ""6. Formatted the final output into the specified JSON structure with empty arrays for unused categories.""]",True,1
6094,,"Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody",,"[""Talquetamab"", ""Pomalidomide"", ""Teclistamab""]",[],"[""Elotuzumab"", ""Pomalidomide"", ""Dexamethasone"", ""Bortezomib""]","[""1. Identified all potential drug names and regimens from the title."", ""2. Analyzed the title structure, identifying the primary arms (Talquetamab + Pomalidomide or Talquetamab + Teclistamab) and comparator arms (Elotuzumab + Pomalidomide + Dexamethasone or Pomalidomide + Bortezomib + Dexamethasone) based on the keyword 'Vs'."", ""3. Classified drugs in the primary arms (Talquetamab, Pomalidomide, Teclistamab) as Primary based on the '+' and 'or' connectors."", ""4. Classified drugs in the comparator arms (Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib) as Comparator."", ""5. Excluded regimen abbreviations 'EPd' and 'PVd' because their full drug components were provided."", ""6. Excluded 'Lenalidomide' and 'Anti-CD38 Monoclonal Antibody' as they were specified as prior therapies, not study treatments."", ""7. Formatted the final lists into the required JSON structure.""]",True,1
4065,,"Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China",,"[""Ixazomib"", ""Lenalidomide"", ""Dexamethasone""]",[],"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]","[""1. Identified drug candidates: Ixazomib, Lenalidomide, Dexamethasone, IRd, Bortezomib, and VRd."", ""2. The keyword 'Comparison of... and...' indicates a comparison between two distinct regimens."", ""3. The first regimen, 'Ixazomib, Lenalidomide Plus Dexamethasone', is identified as the primary study arm. Its components are classified as Primary Drugs."", ""4. The second regimen, 'Bortezomib, Lenalidomide Plus Dexamethasone', is identified as the comparator arm. Its components are classified as Comparator Drugs."", ""5. Excluded the abbreviated regimens 'IRd' and 'VRd' because their full, expanded drug names were provided in the title, per exclusion rules."", ""6. Formatted the final drug lists into the required JSON structure.""]",True,1
3754,,"Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study",,"[""Selinexor"", ""Bortizomib"", ""Dexamethasone""]",[],"[""Bortizomib"", ""Dexamethasone""]","[""1. Identified potential drug names: Selinexor, Bortizomib, Dexamethasone."", ""2. The keyword 'Versus' separates the title into a primary treatment arm and a comparator arm."", ""3. The first arm 'Selinexor, Bortizomib and Dexamethasone' is the main regimen being studied, so Selinexor, Bortizomib, and Dexamethasone are classified as Primary Drugs."", ""4. The second arm 'Bortizomib and Dexamethasone' follows 'Versus', making these drugs Comparators."", ""5. The abbreviated regimens 'SVd' and 'Vd' were excluded because their full drug components were already captured, as per the exclusion rules."", ""6. Formatted the final lists into the required JSON structure.""]",True,1
4151,,Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study,,"[""Glofitamab"", ""Gemcitabine"", ""Oxaliplatin""]",[],"[""Rituximab"", ""Gemcitabine"", ""Oxaliplatin""]","[""1. Identified potential drug names and regimens: Glofitamab, Gemcitabine, Oxaliplatin, Glofit-GemOx, Rituximab, and GemOx (R-GemOx)."", ""2. Analyzed the keyword 'Plus' connecting Glofitamab, Gemcitabine, and Oxaliplatin, identifying them as a single treatment arm."", ""3. Analyzed the keyword 'Versus', which indicates that the subsequent regimen is a comparator."", ""4. Identified the comparator arm as 'Rituximab Plus GemOx', which expands to Rituximab, Gemcitabine, and Oxaliplatin."", ""5. Classified Glofitamab, Gemcitabine, and Oxaliplatin as Primary Drugs."", ""6. Classified Rituximab, Gemcitabine, and Oxaliplatin as Comparator Drugs."", ""7. Excluded the abbreviated regimens (Glofit-GemOx, R-GemOx, GemOx) because their full drug components were explicitly mentioned in the title, following exclusion rules."", ""8. Formatted the final lists and constructed the JSON output.""]",True,1
3971,,Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant,,"[""Glofitamab"", ""Gemcitabine"", ""Oxaliplatin""]",[],"[""Rituximab""]","[""1. Identified potential drug and therapy candidates: Glofitamab, Gemcitabine, Oxaliplatin, Rituximab, and Autologous Stem Cell Transplant."", ""2. Analyzed the title structure, which uses 'Versus' to compare two regimens: '(Glofitamab with Gemcitabine and Oxaliplatin)' versus '(Rituximab with Gemcitabine and Oxaliplatin)'."", ""3. Classified the drugs in the first regimen (Glofitamab, Gemcitabine, Oxaliplatin) as Primary, as they constitute the main therapeutic combination being evaluated."", ""4. Identified Rituximab as the Comparator drug, as it is the key agent differentiating the comparator arm from the primary arm."", ""5. Excluded 'Autologous Stem Cell Transplant' as it is mentioned as part of an exclusion criterion ('not candidates for') and not as a treatment being administered or studied."", ""6. Formatted the extracted drugs into the final JSON output, ensuring no duplicates and correct classification.""]",True,1
5996,,"Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy",,"[""Venetoclax"", ""Azacitidine"", ""Cusatuzumab""]",[],"[""Venetoclax"", ""Azacitidine""]","[""1. Identified potential drug names: Venetoclax, Azacitidine, and Cusatuzumab."", ""2. The keyword 'Versus' separates the primary experimental arm from the comparator arm."", ""3. The phrase 'Venetoclax and Azacitidine Plus Cusatuzumab' identifies the primary treatment regimen, classifying Venetoclax, Azacitidine, and Cusatuzumab as Primary Drugs."", ""4. The phrase 'Venetoclax and Azacitidine Alone' after 'Versus' identifies the comparator treatment, classifying Venetoclax and Azacitidine as Comparator Drugs."", ""5. No keywords indicating secondary drugs were found."", ""6. Assembled the final JSON object with the classified drugs and reasoning trace.""]",True,1
4796,,"Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial",,"[""Decitabine"", ""All-Trans Retinoic Acid""]",[],"[""Decitabine""]","[""1. Identified drug candidates from the title: 'Decitabine' and 'All-Trans Retinoic Acid'."", ""2. Analyzed the keyword 'Plus' connecting 'Decitabine' and 'All-Trans Retinoic Acid', classifying them as co-primary drugs."", ""3. Identified the keyword 'Versus', which establishes the subsequent treatment as the comparator."", ""4. Identified 'Decitabine Monotherapy' as the comparator arm."", ""5. Classified 'Decitabine' and 'All-Trans Retinoic Acid' as Primary Drugs."", ""6. Classified 'Decitabine' from the comparator arm as a Comparator Drug."", ""7. Confirmed no secondary drugs were present based on the absence of relevant keywords."", ""8. Formatted the final JSON output.""]",True,1
4960,,A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL),,"[""Mosunetuzumab"", ""Polatuzumab Vedotin""]",[],"[""Rituximab"", ""Polatuzumab Vedotin""]","[""1. Identified potential drug names: Mosunetuzumab SC, Polatuzumab Vedotin, and Rituximab."", ""2. Analyzed the phrase 'Mosunetuzumab SC Plus Polatuzumab Vedotin' to identify the primary treatment arm. The keyword 'Plus' indicates a combination therapy."", ""3. Analyzed the keyword 'Versus' to identify the comparator arm: 'Rituximab Plus Polatuzumab Vedotin'."", ""4. Classified Mosunetuzumab and Polatuzumab Vedotin as Primary Drugs."", ""5. Classified Rituximab and Polatuzumab Vedotin as Comparator Drugs based on their position after 'Versus'."", ""6. Applied formatting rules, removing the route of administration 'SC' from Mosunetuzumab."", ""7. Assembled the final JSON object with the classified drugs and reasoning trace.""]",True,1
549,,"Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML",,"[""Venetoclax"", ""Azacitidine"", ""Chidamide""]",[],"[""Venetoclax"", ""Azacitidine""]","[""1. Identified the keyword 'Comparing' which indicates a comparison between two treatment arms."", ""2. Identified the first treatment arm as the 'VAC' regimen and the second as the 'VA' regimen."", ""3. Based on the 'Comparing A and B' structure, the first arm (VAC) is classified as Primary and the second arm (VA) as Comparator."", ""4. Extracted the individual drugs from the expanded 'VAC' regimen: Venetoclax, Azacitidine, and Chidamide, and classified them as Primary."", ""5. Inferred the components of the 'VA' regimen from the context of 'VAC' to be Venetoclax and Azacitidine."", ""6. Classified the drugs from the 'VA' regimen, Venetoclax and Azacitidine, as Comparator."", ""7. Excluded the regimen abbreviations 'VAC' and 'VA' because their full components were extracted, as per the rules."", ""8. Formatted the final lists into the required JSON structure.""]",True,1
2954,,"Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)",,"[""Recombinant Human Thrombopoietin""]",[],"[""Eltrombopag""]","[""1. Identified potential drug candidates from the title: 'Recombinant Human Thrombopoietin(rhTPO)' and 'Eltrombopag'."", ""2. Detected the keyword 'Versus', which indicates a comparison between two treatments."", ""3. Classified 'Recombinant Human Thrombopoietin' as the Primary drug, as it is the main subject of the study."", ""4. Classified 'Eltrombopag' as the Comparator drug based on the keyword 'Versus'."", ""5. Excluded the abbreviation 'rhTPO' as the full name was provided, following the preference for expanded forms."", ""6. Assembled the final JSON object with the classified drugs and reasoning trace.""]",True,1
2422,,Lymphodepletion with Fludarabine/Cyclophosphamide Shows Higher Complete Response Rates Compared to Bendamustine Prior to CAR-T Therapy,,"[""Fludarabine"", ""Cyclophosphamide""]",[],"[""Bendamustine""]","[""1. Identified potential drug candidates: Fludarabine, Cyclophosphamide, Bendamustine, and CAR-T Therapy."", ""2. Analyzed keywords: 'with' and '/' indicate Fludarabine and Cyclophosphamide are a primary combination regimen."", ""3. The phrase 'Compared to' clearly identifies Bendamustine as the comparator drug."", ""4. Classified Fludarabine and Cyclophosphamide as Primary drugs."", ""5. Classified Bendamustine as a Comparator drug."", ""6. Excluded 'CAR-T Therapy' as it is the subsequent treatment for which the other drugs are administered as a preparatory (lymphodepletion) regimen, not the agent being directly compared in this study."", ""7. Formatted the final output into the specified JSON structure.""]",True,1
2125,,Comparison of Rabbit ATLG and ATG in Allogeneic Hematopoietic Stem Cell Transplantation for Children with Acquired Severe Aplastic Anemia,,"[""Rabbit ATLG"", ""Allogeneic Hematopoietic Stem Cell""]",[],"[""ATG""]","[""1. Identified potential therapeutic agents from the title: 'Rabbit ATLG', 'ATG', and 'Allogeneic Hematopoietic Stem Cell Transplantation'."", ""2. Normalized 'Allogeneic Hematopoietic Stem Cell Transplantation' to 'Allogeneic Hematopoietic Stem Cell' per cell therapy inclusion rules."", ""3. Analyzed the keyword 'Comparison of... and...' which indicates one agent is being compared against another."", ""4. Classified 'Rabbit ATLG' as the primary drug of interest and 'ATG' as the Comparator based on the comparison structure."", ""5. Classified 'Allogeneic Hematopoietic Stem Cell' as a Primary therapy as it is the backbone treatment in which the comparison is being made."", ""6. Assembled the final JSON object with the classified drugs.""]",True,1
4404,,A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial,,"[""Cytarabine"", ""Venetoclax""]","[""Midostaurin""]",[],"[""1. Identified potential drug names from the title: Cytarabine, Venetoclax, and Midostaurin."", ""2. Analyzed the keyword 'and' connecting 'Cytarabine' and 'Venetoclax', classifying them as co-administered Primary drugs."", ""3. Analyzed the identifier '+/-' (plus/minus) preceding 'Midostaurin', which indicates it is an optional addition to the primary regimen, classifying it as a Secondary drug."", ""4. The term 'Comparing' refers to the internal comparison between the primary regimen with and without the secondary drug, so no external comparator drug was identified."", ""5. Excluded 'Low-Dose' as it is dosage information per exclusion rules."", ""6. Formatted the extracted drugs into the final JSON structure.""]",True,1
3641,,Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial,,"[""Bortezomib"", ""Melphalan"", ""Prednisone""]","[""Daratumumab""]","[""Lenalidomide"", ""Dexamethasone"", ""Daratumumab""]","[""1. Identified drug candidates: Bortezomib, Melphalan, Prednisone, Daratumumab, Lenalidomide, Dexamethasone and regimen abbreviations VMP, DVMP, Rd, DRd."", ""2. Analyzed keywords. 'vs.' separates the primary/secondary arm from the comparator arm. '+/-' identifies a secondary drug."", ""3. In the first arm ('Bortezomib-melphalan-prednisone +/- daratumumab'), Bortezomib, Melphalan, and Prednisone are the core regimen and classified as Primary."", ""4. In the first arm, Daratumumab is preceded by '+/-', classifying it as a Secondary drug."", ""5. The entire second arm ('lenalidomide-dexamethasone +/- daratumumab') follows 'vs.', making all its components Comparator drugs."", ""6. Classified Lenalidomide, Dexamethasone, and Daratumumab from the second arm as Comparator drugs."", ""7. Excluded regimen abbreviations (VMP, DVMP, Rd, DRd) because their expanded drug names are present."", ""8. Formatted the final output into the specified JSON structure.""]",True,1
185,,Beyond Classical Hodgkin Lymphoma: Long-Term Risks and Secondary Cancers-Insights from the Texas Cancer Registry,,[],[],[],"[""1. Scanned the title for any drug names, regimens, or therapeutic agents."", ""2. Identified that the title focuses on disease risks and outcomes ('Long-Term Risks and Secondary Cancers') and a data source ('Texas Cancer Registry')."", ""3. No specific drugs or therapeutic agents administered for treatment were mentioned."", ""4. As no drugs were identified, all categories are empty.""]",True,1
289,,Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease,,[],[],[],"[""1. Analyzed the title for drug names, regimens, or therapeutic agents."", ""2. Identified that the title describes a research methodology and a disease registry, not a specific therapeutic intervention."", ""3. No drug names or therapeutic agents were mentioned in the title."", ""4. Constructed the final JSON with empty arrays for all drug categories.""]",True,1
319,,CSF3RT618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL),,[],[],[],"[""1. Analyzed the title for potential drug names or therapeutic agents."", ""2. Identified terms: 'CSF3RT618I', 'Calnexin', 'Unfolded Protein Response (UPR)', and 'ER-Phagy'."", ""3. 'CSF3RT618I' is a protein mutation and 'Calnexin' is an endogenous protein; both are excluded as they are not administered therapeutically."", ""4. 'Unfolded Protein Response (UPR)' and 'ER-Phagy' are biological processes and are excluded."", ""5. Concluded that no therapeutic drugs are mentioned in the abstract title."", ""6. Generated the final JSON with empty arrays for all drug categories.""]",True,1
340,,Results of the ALL-IC REL 2016 Registry Trial: 1st Relapses of Childhood ALL Treated in High-Middle Income Countries,,[],[],[],"[""1. Scanned the title for drug names, regimens, or therapeutic agents."", ""2. Identified 'ALL-IC REL 2016' as the name of a registry trial, not a drug."", ""3. Identified 'ALL' as Acute Lymphoblastic Leukemia, which is a disease, not a treatment."", ""4. No specific drugs or therapeutic agents intended for treatment were mentioned in the title."", ""5. Concluded that all drug categories are empty.""]",True,1
408,,Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression,,[],[],[],"[""1. Analyzed the title to identify potential drug names."", ""2. Identified 'P-Selectin Expression Assay' as a candidate."", ""3. Determined that 'P-Selectin Expression Assay' is a diagnostic test, not a therapeutic drug, based on the context of the title."", ""4. Excluded the assay per the rule to exclude non-therapeutic items and diagnostic tests."", ""5. Concluded that no therapeutic drugs were mentioned in the title."", ""6. Formatted the output with empty arrays for all drug categories.""]",True,1
450,,"TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial",,"[""V-Rbac""]",[],[],"[""1. Analyzed the title for potential drug names or regimens."", ""2. Identified 'V-Rbac' as a drug regimen from the trial name 'FIL V-Rbac Phase 2 Trial'."", ""3. Excluded 'TP53', 'CD36', and 'CDKN2A' as they are genes/mutations used for outcome prediction, not therapeutic drugs."", ""4. Classified 'V-Rbac' as a Primary drug as it is the regimen being studied in the trial."", ""5. Confirmed no other drugs were mentioned for secondary or comparator classification."", ""6. Formatted the final JSON output.""]",True,1
503,,Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study,,[],[],[],"[""1. Analyzed the title for potential drug names or regimens."", ""2. Identified 'Second Line Therapy' as a general therapy term, not a specific drug."", ""3. Applied the exclusion rule for broad therapy terms."", ""4. Concluded that no specific drugs are mentioned in the title."", ""5. Generated the final JSON with empty arrays for all drug categories.""]",True,1
620,,Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry,,[],[],[],"[""1. Scanned the title for potential drug names or regimens."", ""2. Identified 'Bruton Tyrosine Kinase Inhibitor' and 'Chemotherapy' as candidate terms."", ""3. Excluded 'Bruton Tyrosine Kinase Inhibitor' because it is a mechanism of action/drug class, not a specific drug, according to exclusion rules."", ""4. Excluded 'Chemotherapy' because it is a broad therapy term, as specified in the exclusion rules."", ""5. Determined that no specific therapeutic drugs or regimens are mentioned in the title."", ""6. Generated the final JSON with empty arrays for all drug categories.""]",True,1
641,,"Real World Treatment Outcomes in the First Line Management of Waldenstrom Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical",,[],[],[],"[""1. Scanned the title for any specific drug names, brand names, or therapeutic regimens."", ""2. The title discusses 'Treatment Outcomes' and 'Management' in a general context from a data registry."", ""3. No specific drugs or therapeutic agents intended for treatment were mentioned."", ""4. Concluded that there are no drugs to extract, resulting in empty arrays for all categories.""]",True,1
801,,Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations,,[],[],[],"[""1. Analyzed the abstract title for drug names and therapeutic agents."", ""2. The title focuses on the analysis of patient outcomes and the impact of mutations in a specific patient population and disease."", ""3. No specific drugs, regimens, or therapeutic interventions are mentioned as being administered or studied."", ""4. Concluded that no drugs can be extracted from the title."", ""5. Generated the final JSON with empty arrays for all drug categories.""]",True,1
919,,Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial,,[],[],[],"[""1. Scanned the title for drug names or therapeutic agents."", ""2. Identified 'Gene Therapy' as a potential candidate."", ""3. 'Gene Therapy' is a broad therapy class, not a specific drug, and is excluded per the exclusion rules."", ""4. No specific drugs or regimens were mentioned in the title."", ""5. As no drugs were identified, all categories are returned as empty arrays.""]",True,1
968,,Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party,,"[""Haemopoietic Cell""]",[],[],"[""1. Scanned the title for potential therapeutic agents."", ""2. Identified 'Haemopoietic Cell Transplantation' as a cell-based therapy."", ""3. Applied the cell therapy normalization rule, which requires removing the procedural term 'Transplantation'."", ""4. Normalized 'Haemopoietic Cell Transplantation' to 'Haemopoietic Cell'."", ""5. Classified 'Haemopoietic Cell' as a Primary drug because it is the central therapeutic intervention being studied."", ""6. Confirmed no other drugs or comparators were mentioned in the title."", ""7. Constructed the final JSON object with the extracted drug in the correct category.""]",True,1
1023,,Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry,,[],[],[],"[""1. Analyzed the abstract title for any drug names, regimens, or therapeutic agents."", ""2. The title discusses chromosomal abnormalities and a disease registry, which are related to disease definition and reporting, not treatment."", ""3. No keywords indicating drug administration (e.g., 'with', 'plus', 'versus') were found."", ""4. Concluded that no therapeutic drugs are mentioned in the title."", ""5. Generated the final JSON with empty arrays for all drug categories.""]",True,1
1043,,Real World Efficacies of First Line Treatments in Non-Transplant-Eligible Newly Diagnosed (ND-NTE) Multiple Myeloma (MM) Patients: A Challenge to Maia ? an Analysis from the Austrian Myeloma Registry (AMR),,[],[],"[""Maia""]","[""1. Analyzed the title to identify potential drug or regimen names."", ""2. Identified 'Maia' as a potential regimen, which refers to the regimen studied in the MAIA clinical trial (Daratumumab, Lenalidomide, and Dexamethasone)."", ""3. The phrase 'A Challenge to Maia ?' indicates a comparison between the 'First Line Treatments' being analyzed and the Maia regimen."", ""4. Classified 'Maia' as a Comparator Drug based on the comparative context."", ""5. 'First Line Treatments' is a general therapy term and not a specific drug, so it was excluded."", ""6. No other specific drugs were mentioned for classification as Primary or Secondary."", ""7. Formatted the final output into the specified JSON structure.""]",True,1
1061,,Health Resource Utilization Among Patients with Warm Autoimmune Hemolytic Anemia in Sweden: A Retrospective Registry-Based Study,,[],[],[],"[""1. Analyzed the abstract title: 'Health Resource Utilization Among Patients with Warm Autoimmune Hemolytic Anemia in Sweden: A Retrospective Registry-Based Study'."", ""2. Scanned the title for any drug names, regimens, or therapeutic agents."", ""3. Determined that the title describes a health economics and outcomes research study and does not mention any specific drugs or treatments."", ""4. Concluded that no drugs are present for extraction."", ""5. Formatted the output with empty arrays for all drug categories.""]",True,1
1098,,Complementary and Alternative Medicine (CAM) Use Reported Among Individuals with Immune Thrombocytopenia (ITP): Data from the ITP Natural History Study Registry,,[],[],[],"[""1. Analyzed the title for potential drug names or therapeutic agents."", ""2. Identified 'Complementary and Alternative Medicine (CAM)' as a candidate term."", ""3. Excluded 'CAM' because it is a broad therapy class, not a specific drug, as per the exclusion rules."", ""4. No other specific drugs or regimens were mentioned in the title."", ""5. Generated the final JSON with empty arrays for all drug categories.""]",True,1
1123,,Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas,,[],[],[],"[""Step 1: Analyzed the title for potential drug names or therapeutic agents."", ""Step 2: Identified that the title describes the establishment of a registry and biorepository ('CHIVE Registry and Biorepository')."", ""Step 3: No specific drugs, regimens, or therapeutic agents being administered or studied for treatment were mentioned."", ""Step 4: Concluded that no drugs could be extracted as the title focuses on a registry, not a treatment study."", ""Step 5: Generated the final JSON with empty arrays for all drug categories.""]",True,1
1171,,Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial,,[],[],[],"[""1. Analyzed the title for any potential drug names or therapeutic agents."", ""2. Identified 'PRO-CTCAE' as a reporting standard for adverse events, not a therapeutic drug."", ""3. Confirmed that no specific drugs, regimens, or other therapeutic agents are mentioned in the title."", ""4. Concluded that there are no drugs to extract."", ""5. Formatted the output with empty arrays for all drug categories.""]",True,1
1290,,Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis,,[],[],[],"[""1. Scanned the abstract title for any specific drug names, regimens, or therapeutic agents."", ""2. Identified that the title describes a registry analysis of 'Treatment Patterns and Outcomes' but does not name any specific drugs or treatments."", ""3. Confirmed that no keywords indicating drug relationships (e.g., 'with', 'versus', 'plus') are present in a therapeutic context."", ""4. Concluded that no drugs can be extracted as per the inclusion/exclusion rules."", ""5. Generated the final JSON with empty arrays for all drug categories.""]",True,1
